Mineralys Therapeutics Q3 net loss $36.9M; NDA planned late-2025/Q1 2026; cash $593.6M

Mineralys Therapeutics, Inc.

2025-Q3 EPS reported -$1.94

Net loss $36.9M for Q3 2025 vs $56.3M YoY; R&D expenses fell to $31.5M from $54.0M.
Cash, cash equivalents and investments $593.6M at Sep 30, 2025 (Dec 31, 2024: $198.2M) after $287.5M equity financing.
NDA submission for lorundrostat planned late 2025 or Q1 2026 following pre-NDA FDA feedback.
Enrollment complete in Explore-OSA Phase 2 trial; topline data anticipated Q1 2026.
Company expects current cash to fund planned clinical and regulatory activities into 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.